Study of toripalimab before surgery for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests toripalimab (an immunotherapy) given before surgery for untreated head and neck squamous cell carcinoma, either alone or with chemotherapy. The goal is to shrink or control the cancer earlier and see if it improves outcomes for people who plan curative surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed head and neck squamous cell carcinoma (HNSCC) and are planning surgery with curative intent.
- Your age is 18 to under 80 when you start the study.
- You feel well enough for treatment (ECOG 0 or 1).
- Your cancer is measurable on scans (meeting RECIST 1.1).
- You have not taken prior immune treatments that target checkpoints like PD-1/PD-L1/PD-L2 or CTLA-4.
- Blood tests and organ function (liver, kidneys, blood counts) must meet specific thresholds within 14 days before enrollment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two immunotherapy drugs before surgery is better than one alone for advanced head and neck cancer. The goal is to see if the combination can shrink tumors more and improve outcomes.
This trial tests whether giving tislelizumab (an immunotherapy) with chemotherapy before surgery works better than surgery alone for people with head and neck cancer that has not spread to lymph nodes. It's for cancers that can be removed with surgery, and the goal is to see if the pre-surgery treatment improves outcomes.
This trial tests a new immunotherapy drug (adelbelimab) combined with chemotherapy given before surgery, for people with head and neck cancer. The goal is to see if this combination can shrink the tumor and improve the chances of successful surgery.
This Phase 2 trial tests tirelizumab combined with two chemotherapy medicines before surgery for certain head and neck squamous cell cancers. It aims to shrink the tumor and improve outcomes after the operation.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.